Pfizer Recalls 28 Lots of Birth Control Pills

Martha Kerr

February 01, 2012

February 1, 2012 — Pfizer Inc announced yesterday that it has voluntarily recalled 14 lots of norgestrel and ethinyl estradiol tablets and 14 lots of the brand-name version of the oral contraceptive, Lo/Ovral-28, from the US market.

An internal investigation revealed that some blister packs "may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence," Pfizer said in a press release.

The company says the cause was identified and corrected immediately.

Pfizer manufactures the tablets, which are commercialized by Akrimax Rx Products and labeled under the Akrimax Pharmaceuticals brand. The oral contraceptive is distributed nationwide.

"As a result of this packaging error, the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy," Pfizer warned.

The packaging defects in themselves do not pose any immediate health risk, but women who may have taken the contraceptive "should begin using a non-hormonal form of contraception immediately," notify their physician, and return the product to the pharmacy from which they obtained it, the company advises.

Recalled lot numbers are listed in the Pfizer press release, which is available on the FDA Web site.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.